Here's How Much a $1000 Investment in Eli Lilly Made 10 Years Ago Would Be Worth Today

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.What if you'd invested in Eli Lilly (LLY) ten years ago? It may not have been easy to hold on to LLY for all that time, but if you did, how much would your investment be worth today?Eli Lilly's Business In-DepthWith that in mind, let's take a look at Eli Lilly's main business drivers.Indianapolis, IN-based Eli Lilly and Company, one of the world’s largest pharmaceutical companies, boasts a diversified product profile, including a solid lineup of new successful drugs. It also has a dependable pipeline in areas like obesity, diabetes and Alzheimer’s.Its pharmaceutical product categories are cardiometabolic health (Mounjaro, Zepbound, Trulicity and others), neuroscience (Cymbalta, Emgality and others), oncology (Alimta, Cyramza, Verzenio and others), immunology (Taltz, Omvoh and Olumiant and others) and others (Cialis and others). Lilly’s key acquisitions include Hypnion (a neuroscience drug discovery company focused on sleep disorders), CoLucid Pharmaceuticals (which added Reyvow for acute migraine), Loxo Oncology (added cancer drugs Retevmo and Jaypirca), Dermira (added atopic dermatitis drug Ebglyss/lebrikizumab), Akouos (expanded efforts in genetic medicines), DICE Therapeutics (strengthened immunology pipeline) and Morphic Therapeutics (added oral integrin therapies for treating serious chronic diseases) and Adverum Biotechnologies (added one-time intravitreal gene therapy Ixo-vec for retinal diseases).Lilly has collaboration agreements with several companies, including Incyte (Olumiant), Boehringer Ingelheim (diabetes) and Roche (Ebglyss) among others.    Lilly divested its Elanco animal health unit as an independent publicly traded company - Elanco Animal Health Incorporated - via an initial public offering (IPO) of a minority stake in 2018. Elanco Animal Health started trading with the ticker symbol ELAN on NYSE on Sept. 20, 2018. Lilly divested the remaining 80.2% stake in the new company through a “tax-efficient transaction” in March 2019. Lilly’s 2025 revenues increased 45% to $65.2 billion. Among the key drugs, Mounjaro accounted for around 35.2% of Lilly’s 2025 revenues, Zepbound 20.8%, Verzenio 8.8%, and Taltz and Jardiance accounted for slightly more than 7% each of the total revenues.  Bottom LineAnyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Eli Lilly a decade ago, you're probably feeling pretty good about your investment today.A $1000 investment made in June 2016 would be worth $16,253.46, or a 1,525.35% gain, as of June 29, 2026, according to our calculations. Investors should note that this return excludes dividends but includes price increases.In comparison, the S&P 500's gained 260.95% and the price of gold went up 196.91% over the same time frame.Looking ahead, analysts are expecting more upside for LLY.Demand for Lilly's popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company's key top-line drivers. Lilly's other new drugs like Kisunla, Omvoh and Jaypirca are also contributing to top-line growth. It is also making rapid pipeline progress in obesity and diabetes with its new oral GLP-1 obesity pill, Foundayo, expected to be a commercial game-changer for Lilly. Over the past couple of years, Lilly has announced several M&A deals aimed at diversifying beyond GLP-1 drugs and expanding its presence in cardiovascular, oncology, and neuroscience. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 market are some top-line headwinds. The stock has outperformed the industry in the past year.Shares have gained 9.33% over the past four weeks and there have been 9 higher earnings estimate revisions for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.See Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks